APRE vs DXCM · $10.4M cap vs P/E 63, rev $2.50B
Aprea Therapeutics Inc (APRE) versus DexCom Inc (DXCM) — a side-by-side from cached financials, not a winner call.
Aprea Therapeutics Inc (APRE) is a biotechnology company listed on US.
DexCom Inc (DXCM) is a medical devices company listed on US.
APRE does not have a complete income-statement cache yet.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
APRE currently screens at market cap $10.4M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Not investment advice. Open the APRE and DXCM stock pages for the full models.
Not investment advice.